Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Reported by The New England Journal of Medicine. Read the original →
The headline reports on a study regarding the cardiovascular and renal outcomes associated with Efpeglenatide in individuals with type 2 diabetes. The specifics of the findings or methodology are not provided in the description.
Summarised by a model from The New England Journal of Medicine's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
- Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.Human · RCT · 2023
- Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial.Human · Observational · 2026
- Durable platelet response and immature platelet indices following sequential efgartigimod and eltrombopag therapy in a patient with refractory ITP.Human · Case report · n=1 · 2026
What the headline doesn't tell you
- Efpeglenatide has 8 studies on file, 6 of them in humans, the newest published 2026.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.